CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: hepatitis B vaccine</title> <meta name="description" content="Search results for: hepatitis B vaccine"> <meta name="keywords" content="hepatitis B vaccine"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="hepatitis B vaccine" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="hepatitis B vaccine"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 356</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: hepatitis B vaccine</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">356</span> Uptake of Hepatitis B Vaccine among Hepatitis C Positive Patients and Their Vaccine Response in Myanmar</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zaw%20Z%20Aung">Zaw Z Aung</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: High-risk groups for hepatitis B infection (HBV) are people who injected drugs (PWID), men who have sex with men (MSM), people living with HIV (PLHIV) and persons with hepatitis C (HCV), etc. HBV/HCV coinfected patients are at increased risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma. To the best of author’s knowledge, there is currently no data for hepatitis B vaccine utilization in HCV positive patients and their antibody response. Methodology: From February 2018 to May 2018, consented participants at or above 18 years who came to the clinic in Mandalay were tested with the anti-HCV rapid test. Those who tested HCV positive (n=168) were further tested with hepatitis B profile and asked about their previous hepatitis B vaccination history and risk factors. Results: Out of 168 HCV positive participants, three were excluded for active HBV infections. The remaining 165 were categorized into previously vaccinated 64% (n=106) and unvaccinated 36% (n=59) There were three characteristics groups- PWID monoinfected (n=77), General Population (GP) monoinfected (n=22) and HIV/HCV coinfected participants (n=66). Unvaccinated participants were highest in HIV/HCV, with 68%(n=45) followed by GP (23%, n=5) and PWID (12%, n=9). Among previously vaccinated participants, the highest percentage was PWID (88%, n=68), the second highest was GP (77%, n=17) and lowest in HIV/HCV patients (32%, n=21). 63 participants completed third doses of vaccination (PWID=36, GP=13, HIV/HCV=14). 53% of participants who completed 3 dose of hepatitis B were non-responders (n=34): HIV/HCV (86%, n=12), PWID (44%, n=16), and GP (46%, n=6) Conclusion: Even in the presence of effective and safe hepatitis B vaccine, uptake is low among high risk groups especially PLHIV that needs to be improved. Integration or collaboration of hepatitis B vaccination program, HIV/AIDS and hepatitis C treatment centers is desirable. About half of vaccinated participants were non-responders so that optimal doses, schedule and follow-up testing need to be addressed carefully for those groups. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C" title=" Hepatitis C"> Hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=HIV" title=" HIV"> HIV</a>, <a href="https://publications.waset.org/abstracts/search?q=Myanmar" title=" Myanmar"> Myanmar</a> </p> <a href="https://publications.waset.org/abstracts/97724/uptake-of-hepatitis-b-vaccine-among-hepatitis-c-positive-patients-and-their-vaccine-response-in-myanmar" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97724.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">145</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">355</span> Methylprednisolone Injection Did Not Inhibit Anti-Hbs Response Following Hepatitis B Vaccination in Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Ughachukwu">P. O. Ughachukwu</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Okonkwo"> P. O. Okonkwo</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20C.%20Unekwe"> P. C. Unekwe</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20O.%20Ogamba"> J. O. Ogamba</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The prevalence of hepatitis B viral infection is high worldwide with liver cirrhosis and hepatocellular carcinoma as important complications. Cases of poor antibody response to hepatitis B vaccination abound. Immunosuppression, especially from glucocorticoids, is often cited as a cause of poor antibody response and there are documented evidences of irrational administration of glucocorticoids to children and adults. The study was, therefore, designed to find out if administration of glucocorticoids affects immune response to vaccination against hepatitis B in mice. Methods: Mice of both sexes were randomly divided into 2 groups. Daily intramuscular methylprednisolone injections, (15 mg kg-1), were given to the test group while sterile deionized water (0.1ml) was given to control mice for 30 days. On day 6 all mice were given 2 μg (0.1ml) hepatitis B vaccine and a booster dose on day 27. On day 34, blood samples were collected and analyzed for anti-HBs titres using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was done using Graph Pad Prism 5.0 and the results taken as statistically significant at p value < 0.05. Results: There were positive serum anti-HBs responses in all mice groups but the differences in titres were not statistically significant. Conclusions: At the dosages and length of exposure used in this study, methylprednisolone injection did not significantly inhibit anti-HBs response in mice following immunization against hepatitis B virus. By extrapolation, methylprednisolone, when used in the usual clinical doses and duration of therapy, is not likely to inhibit immune response to hepatitis B vaccinations in man. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-HBs" title="anti-HBs">anti-HBs</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine" title=" hepatitis B vaccine"> hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20response" title=" immune response"> immune response</a>, <a href="https://publications.waset.org/abstracts/search?q=methylprednisolone" title=" methylprednisolone"> methylprednisolone</a>, <a href="https://publications.waset.org/abstracts/search?q=mice" title=" mice"> mice</a> </p> <a href="https://publications.waset.org/abstracts/28711/methylprednisolone-injection-did-not-inhibit-anti-hbs-response-following-hepatitis-b-vaccination-in-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28711.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">323</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">354</span> Hepatitis B Vaccination Status and Its Determinants among Primary Health Care Workers in Northwest Pakistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Tahir%20Yousafzai">Mohammad Tahir Yousafzai</a>, <a href="https://publications.waset.org/abstracts/search?q=Rubina%20Qasim"> Rubina Qasim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We assessed Hepatitis B vaccination and its determinants among health care workers (HCW) in Northwest Pakistan. HCWs from both public and private clinics were interviewed about hepatitis B vaccination, socio-demographic, hepatitis B virus transmission modes, disease threat and benefits of vaccination. Logistic regression was performed. Hepatitis B vaccination was 40% (Qualified Physicians: 86% and non-qualified Dispensers:16%). Being Qualified Physician (Adj. OR 26.6; 95%CI 9.3-73.2), Non-qualified Physician (Adj.OR 1.9; 95%CI 0.8-4.6), qualified Dispensers (Adj. OR 3.6; 95%CI 1.3-9.5) compared to non-qualified Dispensers, working in public clinics (Adj. OR 2.5; 95%CI 1.1-5.7) compared to private, perceived disease threat after exposure to blood and body fluids (Adj. OR 1.1; 95%CI 1.1-1.2) and perceived benefits of vaccination (Adj. OR 1.1; 95%CI 1.1-1.2) were significant predictors of hepatitis B vaccination. Improved perception of disease threat and benefits of vaccination and qualification of HCWs are associated with hepatitis B vaccination. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immunization" title=" immunization"> immunization</a>, <a href="https://publications.waset.org/abstracts/search?q=healthcare%20workers" title=" healthcare workers"> healthcare workers</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20health" title=" primary health "> primary health </a> </p> <a href="https://publications.waset.org/abstracts/13926/hepatitis-b-vaccination-status-and-its-determinants-among-primary-health-care-workers-in-northwest-pakistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13926.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">315</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">353</span> Optimization of Hepatitis B Surface Antigen Purifications to Improving the Production of Hepatitis B Vaccines on Pichia pastoris</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rizky%20Kusuma%20Cahyani">Rizky Kusuma Cahyani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis B is a liver inflammatory disease caused by hepatitis B virus (HBV). This infection can be prevented by vaccination which contains HBV surface protein (sHBsAg). However, vaccine supply is limited. Several attempts have been conducted to produce local sHBsAg. However, the purity degree and protein yield are still inadequate. Therefore optimization of HBsAg purification steps is required to obtain high yield with better purification fold. In this study, optimization of purification was done in 2 steps, precipitation using variation of NaCl concentration (0,3 M; 0,5 M; 0,7 M) and PEG (3%, 5%, 7%); ion exchange chromatography (IEC) using NaCl 300-500 mM elution buffer concentration.To determine HBsAg protein, bicinchoninic acid assay (BCA) and enzyme-linked immunosorbent assay (ELISA) was used in this study. Visualization of HBsAg protein was done by SDS-PAGE analysis. Based on quantitative analysis, optimal condition at precipitation step was given 0,3 M NaCl and PEG 3%, while in ion exchange chromatography step, the optimum condition when protein eluted with NaCl 500 mM. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis indicates that the presence of protein HBsAg with a molecular weight of 25 kDa (monomer) and 50 kDa (dimer). The optimum condition for purification of sHBsAg produced in Pichia pastoris gave a yield of 47% and purification fold 17x so that it would increase the production of hepatitis B vaccine to be more optimal. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title="hepatitis B virus">hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=HBsAg" title=" HBsAg"> HBsAg</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen" title=" hepatitis B surface antigen"> hepatitis B surface antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=Pichia%20pastoris" title=" Pichia pastoris"> Pichia pastoris</a>, <a href="https://publications.waset.org/abstracts/search?q=purification" title=" purification"> purification</a> </p> <a href="https://publications.waset.org/abstracts/91001/optimization-of-hepatitis-b-surface-antigen-purifications-to-improving-the-production-of-hepatitis-b-vaccines-on-pichia-pastoris" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/91001.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">352</span> The Need for Including Hepatitis a Vaccine in Routine Childhood Immunization Programs in Europe as a Response to the Influx of Refugees from the Middle East and North Africa (MENA) Regions</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Ramia">S. Ramia</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Melhem"> N. Melhem</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Kreidieh"> K. Kreidieh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The world is facing an unprecedented displacement crisis. Recently, over 1.1 million asylum seekers have been granted protection status in the European Union (EU). The majority of these asylum seekers were from countries of the Middle East and North Africa (MENA) region.This influx carries with it a potential introduction of infectious diseases that have been eliminated in the EU, which poses a challenge for EU health authorities. Compared to MENA region countries where Hepatitis A Virus (HAV) endemicity is high to intermediate, member states of the EU show very low (Western Europe) to low (Eastern Europe) levels of HAV endemicity. Because of this situation, there is an ongoing public health concern in high-income countries, like members of the EU, that many adults remain susceptible to HAV outbreaks. The overwhelming majority of the EU members’ states do not include HAV vaccine in their immunization calendars. Hence, this paper urgently calls for the implementation of new policies regarding HAV in EU members’ states. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=European%20union" title="European union">European union</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20A" title=" hepatitis A"> hepatitis A</a>, <a href="https://publications.waset.org/abstracts/search?q=MENA%20region%20refugees" title=" MENA region refugees"> MENA region refugees</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine%20preventable%20diseases" title=" vaccine preventable diseases"> vaccine preventable diseases</a> </p> <a href="https://publications.waset.org/abstracts/61472/the-need-for-including-hepatitis-a-vaccine-in-routine-childhood-immunization-programs-in-europe-as-a-response-to-the-influx-of-refugees-from-the-middle-east-and-north-africa-mena-regions" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/61472.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">278</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">351</span> A Vaccination Program to Control an Outbreak of Acute Hepatitis A among MSM in Taiwan, 2016</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ying-Jung%20Hsieh">Ying-Jung Hsieh</a>, <a href="https://publications.waset.org/abstracts/search?q=Angela%20S.%20Huang"> Angela S. Huang</a>, <a href="https://publications.waset.org/abstracts/search?q=Chu-Ming%20Chiu"> Chu-Ming Chiu</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu-Min%20Chou"> Yu-Min Chou</a>, <a href="https://publications.waset.org/abstracts/search?q=Chin-Hui%20Yang"> Chin-Hui Yang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objectives: Hepatitis A is primarily acquired by the fecal-oral route through person-to-person contact or ingestion of contaminated food or water. During 2010 to 2014, an average of 83 cases of locally-acquired disease was reported to Taiwan’s notifiable disease system. Taiwan Centers for Disease Control (TCDC) identified an outbreak of acute hepatitis A which began in June 2015. Of the 126 cases reported in 2015, 103 (82%) cases were reported during June–December and 95 cases (92%) of them were male. The average age of all male cases was 31 years (median, 29 years; range, 15–76 years). Among the 95 male cases, 49 (52%) were also infected with HIV, and all reported to have had sex with other men. To control this outbreak, TCDC launched a free hepatitis A vaccination program in January 2016 for close contacts of confirmed hepatitis A cases, including family members, sexual partners, and household contacts. Effect of the vaccination program was evaluated. Methods: All cases of hepatitis A reported to the National Notifiable Disease Surveillance System were included. A case of hepatitis A was defined as a locally-acquired disease in a person who had acute clinical symptoms include fever, malaise, loss of appetite, nausea or abdominal discomfort compatible with hepatitis, and tested positive for anti-HAV IgM during June 2015 to June 2016 in Taiwan. The rate of case accumulation was calculated using a simple regression model. Results: During January–June 2016, there were 466 cases of hepatitis A reported; of the 243 (52%) who were also infected with HIV, 232 (95%) had a history of having sex with men. Of the 346 cases that were followed up, 259 (75%) provided information on contacts but only 14 (5%) of them provided the name of their sexual partners. Among the 602 contacts reported, 349 (58%) were family members, 14 (2%) were sexual partners, and 239 (40%) were other household contacts. Among the 602 contacts eligible for free hepatitis A vaccination, 440 (73%) received the vaccine. There were 87 (25%) cases that refused to disclose their close contacts. The average case accumulation rate during January–June 2016 was 21.7 cases per month, which was 6.8 times compared to the average case accumulation rate during June–December 2015 of 3.2 cases per month. Conclusions: Despite vaccination program aimed to provide free hepatitis A vaccine to close contacts of hepatitis A patients, the outbreak continued and even gained momentum in transmission. Refusal by hepatitis A patients to provide names of their close contacts and rejection of contacts to take the hepatitis A vaccine may have contributed to the poor effect of the program. Targeted vaccination efforts of all MSM may be needed to control the outbreak among this population in the short term. In the long term, universal vaccination program is needed to prevent the infection of hepatitis A. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20A" title="hepatitis A">hepatitis A</a>, <a href="https://publications.waset.org/abstracts/search?q=HIV" title=" HIV"> HIV</a>, <a href="https://publications.waset.org/abstracts/search?q=men%20who%20have%20sex%20with%20men" title=" men who have sex with men"> men who have sex with men</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccination" title=" vaccination"> vaccination</a> </p> <a href="https://publications.waset.org/abstracts/56588/a-vaccination-program-to-control-an-outbreak-of-acute-hepatitis-a-among-msm-in-taiwan-2016" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56588.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">256</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">350</span> Lentiviral-Based Novel Bicistronic Therapeutic Vaccine against Chronic Hepatitis B Induces Robust Immune Response</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20F.%20Jamiluddin">Mohamad F. Jamiluddin</a>, <a href="https://publications.waset.org/abstracts/search?q=Emeline%20Sarry"> Emeline Sarry</a>, <a href="https://publications.waset.org/abstracts/search?q=Ana%20Bejanariu"> Ana Bejanariu</a>, <a href="https://publications.waset.org/abstracts/search?q=C%C3%A9cile%20Bauche"> Cécile Bauche </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Over 360 million people are chronically infected with hepatitis B virus (HBV), of whom 1 million die each year from HBV-associated liver cirrhosis or hepatocellular carcinoma. Current treatment options for chronic hepatitis B depend on interferon-α (IFNα) or nucleos(t)ide analogs, which control virus replication but rarely eliminate the virus. Treatment with PEG-IFNα leads to a sustained antiviral response in only one third of patients. After withdrawal of the drugs, the rebound of viremia is observed in the majority of patients. Furthermore, the long-term treatment is subsequently associated with the appearance of drug resistant HBV strains that is often the cause of the therapy failure. Among the new therapeutic avenues being developed, therapeutic vaccine aimed at inducing immune responses similar to those found in resolvers is of growing interest. The high prevalence of chronic hepatitis B necessitates the design of better vaccination strategies capable of eliciting broad-spectrum of cell-mediated immunity(CMI) and humoral immune response that can control chronic hepatitis B. Induction of HBV-specific T cells and B cells by therapeutic vaccination may be an innovative strategy to overcome virus persistence. Lentiviral vectors developed and optimized by THERAVECTYS, due to their ability to transduce non-dividing cells, including dendritic cells, and induce CMI response, have demonstrated their effectiveness as vaccination tools. Method: To develop a HBV therapeutic vaccine that can induce a broad but specific immune response, we generated recombinant lentiviral vector carrying IRES(Internal Ribosome Entry Site)-containing bicistronic constructs which allow the coexpression of two vaccine products, namely HBV T- cell epitope vaccine and HBV virus like particle (VLP) vaccine. HBV T-cell epitope vaccine consists of immunodominant cluster of CD4 and CD8 epitopes with spacer in between them and epitopes are derived from HBV surface protein, HBV core, HBV X and polymerase. While HBV VLP vaccine is a HBV core protein based chimeric VLP with surface protein B-cell epitopes displayed. In order to evaluate the immunogenicity, mice were immunized with lentiviral constructs by intramuscular injection. The T cell and antibody immune responses of the two vaccine products were analyzed using IFN-γ ELISpot assay and ELISA respectively to quantify the adaptive response to HBV antigens. Results: Following a single administration in mice, lentiviral construct elicited robust antigen-specific IFN-γ responses to the encoded antigens. The HBV T- cell epitope vaccine demonstrated significantly higher T cell immunogenicity than HBV VLP vaccine. Importantly, we demonstrated by ELISA that antibodies are induced against both HBV surface protein and HBV core protein when mice injected with vaccine construct (p < 0.05). Conclusion: Our results highlight that THERAVECTYS lentiviral vectors may represent a powerful platform for immunization strategy against chronic hepatitis B. Our data suggests the likely importance of Lentiviral vector based novel bicistronic construct for further study, in combination with drugs or as standalone antigens, as a therapeutic lentiviral based HBV vaccines. THERAVECTYS bicistronic HBV vaccine will be further evaluated in animal efficacy studies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B" title="chronic hepatitis B">chronic hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=lentiviral%20vectors" title=" lentiviral vectors"> lentiviral vectors</a>, <a href="https://publications.waset.org/abstracts/search?q=therapeutic%20vaccine" title=" therapeutic vaccine"> therapeutic vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=virus-like%20particle" title=" virus-like particle"> virus-like particle</a> </p> <a href="https://publications.waset.org/abstracts/34143/lentiviral-based-novel-bicistronic-therapeutic-vaccine-against-chronic-hepatitis-b-induces-robust-immune-response" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34143.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">349</span> Reforms in China's Vaccine Administration: Vulnerabilities, Legislative Progresses and the Systemic View of Vaccine Administration Law</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Lin%20Tang">Lin Tang</a>, <a href="https://publications.waset.org/abstracts/search?q=Xiaoxia%20Guo"> Xiaoxia Guo</a>, <a href="https://publications.waset.org/abstracts/search?q=Lingling%20Zhang"> Lingling Zhang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Recent vaccine scandals overshadowed China’s accomplishment of public health, triggering discussions on the causes of vaccine incidents. Through legal interpretation of selected vaccine incidents and analysis of systemic vulnerabilities in vaccine circulation and lot release, a panoramic review of legislative progresses in the vaccine administration sheds the light on this debate. In essence, it is the combination of the lagging legal system and the absence of information technology infrastructure in the process of vaccine administration reform that has led to the recurrence of vaccine incidents. These findings have significant implications for further improvement of vaccine administration and China’s participation in global healthcare. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=legislation" title="legislation">legislation</a>, <a href="https://publications.waset.org/abstracts/search?q=lot%20release" title=" lot release"> lot release</a>, <a href="https://publications.waset.org/abstracts/search?q=public%20health" title=" public health"> public health</a>, <a href="https://publications.waset.org/abstracts/search?q=reform" title=" reform"> reform</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine%20administration" title=" vaccine administration"> vaccine administration</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine%20circulation" title=" vaccine circulation"> vaccine circulation</a> </p> <a href="https://publications.waset.org/abstracts/143772/reforms-in-chinas-vaccine-administration-vulnerabilities-legislative-progresses-and-the-systemic-view-of-vaccine-administration-law" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/143772.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">152</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">348</span> Acute Hepatitis A Outbreak in Men Who Has Sex with Men in a Medical Center in Northern Taiwan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yu-Tzu%20Hsu">Yu-Tzu Hsu</a>, <a href="https://publications.waset.org/abstracts/search?q=Alice%20Wu"> Alice Wu</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsiang-Kuang%20Tseng"> Hsiang-Kuang Tseng</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatitis A virus causes acute hepatitis and is usually transmitted by a fecal-oral route of food contamination, which is more prevalent in areas with poor hygienic practices. However, we described a hepatitis A outbreak associated with a fecal-oral route of sexual behavior in men who has sex with men (MSM) in Northern Taiwan. Methods: We retrospectively collected patients with acute HAV infection in MacKay Memorial Hospital, Taipei, Taiwan between July 2015 and November 2016. Demographic data (age, gender, onset time and infection risk), laboratory data (GOT, GPT, bilirubin, HIV status, HBsAg, HCV antibody and syphilis), clinical symptoms and travel history with a foreign tour were analyzed. We compared variables between HIV and non-HIV group. Unless otherwise stated, continuous variables were expressed as mean ± SD, and categorical variables were expressed as number (percentage) for each item. The t test for continuous variables was applied for the comparison between two groups and chi-square for categorical variables were applied for measures of association. Results: We collected 80 cases during the study period. Among them, 54 (67.5%) cases were MSM and 43 (53.8%) cases were HIV positive. The average age was 32.6±7.59 years-old. The average value of initial liver function was 1324 IU/L for AST (GOT), 2100 IU/L for ALT (GPT), and 5.82 mg/dL for bilirubin. We found seven (8.6%) cases were in the status of HBV carrier, five (6.3%) cases were positive for HCV antibody, and 15 (18.6%) cases were co-infected with syphilis. With regards to associated symptoms, 32 (40%) had fever, 46 (57.5%) had nausea, 34 (42.5%) had abdominal discomfort and 46 (57.5%) had general malaise. To compare the non-HIV patients with HIV patients, HIV patients were more likely to be male (p=0.008), MSM (p=0.000), co-infected syphilis (p=0.000) and slowly improving liver function of transaminases (p=0.033, 0.027). Conclusion: The HAV outbreak in Northern Taiwan was mainly occurred in MSM population. Hereafter, our cohort data support a policy in Taiwan to provide one dose of free HAV vaccine shot in this population. Hopefully, the outbreak could be stop by the free vaccine policy and public education. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20hepatitis%20A" title="acute hepatitis A">acute hepatitis A</a>, <a href="https://publications.waset.org/abstracts/search?q=men%20who%20has%20sex%20with%20men" title=" men who has sex with men"> men who has sex with men</a>, <a href="https://publications.waset.org/abstracts/search?q=human%20immunodeficiency%20virus" title=" human immunodeficiency virus"> human immunodeficiency virus</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine" title=" vaccine"> vaccine</a> </p> <a href="https://publications.waset.org/abstracts/80910/acute-hepatitis-a-outbreak-in-men-who-has-sex-with-men-in-a-medical-center-in-northern-taiwan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/80910.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">203</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">347</span> Molecular Farming: Plants Producing Vaccine and Diagnostic Reagent</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Katerina%20H.%20Takova">Katerina H. Takova</a>, <a href="https://publications.waset.org/abstracts/search?q=Ivan%20N.%20Minkov"> Ivan N. Minkov</a>, <a href="https://publications.waset.org/abstracts/search?q=Gergana%20G.%20Zahmanova"> Gergana G. Zahmanova</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Molecular farming is the production of recombinant proteins in plants with the aim to use the protein as a purified product, crude extract or directly in the planta. Plants gain more attention as expression systems compared to other ones due to the cost effective production of pharmaceutically important proteins, appropriate post-translational modifications, assembly of complex proteins, absence of human pathogens to name a few. In addition, transient expression in plant leaves enables production of recombinant proteins within few weeks. Hepatitis E virus (HEV) is a causative agent of acute hepatitis. HEV causes epidemics in developing countries and is primarily transmitted through the fecal-oral route. Presently, all efforts for development of Hepatitis E vaccine are focused on the Open Read Frame 2 (ORF2) capsid protein as it contains epitopes that can induce neutralizing antibodies. For our purpose, we used the CMPV-based vector-pEAQ-HT for transient expression of HEV ORF2 in Nicotiana benthamina. Different molecular analysis (Western blot and ELISA) showed that HEV ORF2 capsid protein was expressed in plant tissue in high-yield up to 1g/kg of fresh leaf tissue. Electron microscopy showed that the capsid protein spontaneously assembled in low abundance virus-like particles (VLPs), which are highly immunogenic structures and suitable for vaccine development. The expressed protein was recognized by both human and swine HEV positive sera and can be used as a diagnostic reagent for the detection of HEV infection. Production of HEV capsid protein in plants is a promising technology for further HEV vaccine investigations. Here, we reported for a rapid high-yield transient expression of a recombinant protein in plants suitable for vaccine production as well as a diagnostic reagent. Acknowledgments -The authors’ research on HEV is supported with grants from the Project PlantaSYST under the Widening Program, H2020 as well as under the UK Biotechnological and Biological Sciences Research Council (BBSRC) Institute Strategic Programme Grant ‘Understanding and Exploiting Plant and Microbial Secondary Metabolism’ (BB/J004596/1). The authors want to thank Prof. George Lomonossoff (JIC, Norwich, UK) for his contribution. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20E%20virus" title="hepatitis E virus">hepatitis E virus</a>, <a href="https://publications.waset.org/abstracts/search?q=plant%20molecular%20farming" title=" plant molecular farming"> plant molecular farming</a>, <a href="https://publications.waset.org/abstracts/search?q=transient%20expression" title=" transient expression"> transient expression</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccines" title=" vaccines"> vaccines</a> </p> <a href="https://publications.waset.org/abstracts/90648/molecular-farming-plants-producing-vaccine-and-diagnostic-reagent" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/90648.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">346</span> Analysis of Post-vaccination Immunity in Children with Severe Chronic Diseases Receiving Immunosuppressive Therapy by Specific IgG Antibodies Definition Method</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Marina%20G.%20Galitskaya">Marina G. Galitskaya</a>, <a href="https://publications.waset.org/abstracts/search?q=Svetlana%20G.%20Makarova"> Svetlana G. Makarova</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrey%20P.%20Fisenko."> Andrey P. Fisenko.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Children on medication-induced immunosuppression are at high risk of developing severe course infectious diseases. Therefore, preventive vaccination is especially important for these children. However, due to the immunosuppressive effects of treatment for the underlying disease, the effectiveness of vaccination may decrease below the protective level. In a multidisciplinary children's medical center, post-vaccination immunity was studied in 79 children aged 4-17 years. The children were divided into 2 groups: Group 1 (38 children) with kidney pathology (Nephrotic Syndrome) and Group 2 (41 children) with inflammatory bowel diseases (Ulcerative Colitis, Crohn's Disease). Both groups of children were vaccinated according to the national vaccination calendar and received immunosuppressive therapy (prednisolone, methotrexate, cyclosporine, and other drugs) for at least 1 year. Using the enzyme-linked immunosorbent assay method, specific IgG antibodies to vaccine-preventable infections were determined: measles, rubella, mumps, diphtheria, pertussis, tetanus, and hepatitis B. The study showed the percentage of children with positive IgG values for vaccine-preventable infections. The highest percentage of children had protective antibody levels to measles (84.2% in children with nephrotic syndrome and 92.6% in those with inflammatory bowel disease) and rubella (71% and 80.4%, respectively). The lowest percentage of children with protective antibodies was for hepatitis B (5.2% and 29.2% respectively). Antibodies to mumps, diphtheria, pertussis, and tetanus were found not in all children (from 39,4% to 82,9%). The remaining percentage of children did not have detectable IgG antibodies to vaccine-preventable infections. Not all children, despite the previous vaccination, preserved antibodies to vaccine-controlled infections and remained unprotected by specific IgG antibodies. The issue of a booster vaccine dose should be considered in children without contraindications to vaccination. Children receiving long-term immunosuppressive therapy require an individual vaccination approach, including a specific definition of the performed vaccination. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=immunosuppressive%20therapy" title="immunosuppressive therapy">immunosuppressive therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=inflammatory%20bowel%20diseases" title=" inflammatory bowel diseases"> inflammatory bowel diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=nephrotic%20syndrome" title=" nephrotic syndrome"> nephrotic syndrome</a>, <a href="https://publications.waset.org/abstracts/search?q=post-vaccination%20immunity" title=" post-vaccination immunity"> post-vaccination immunity</a>, <a href="https://publications.waset.org/abstracts/search?q=specific%20antibodies" title=" specific antibodies"> specific antibodies</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine-preventable%20infections." title=" vaccine-preventable infections."> vaccine-preventable infections.</a> </p> <a href="https://publications.waset.org/abstracts/186797/analysis-of-post-vaccination-immunity-in-children-with-severe-chronic-diseases-receiving-immunosuppressive-therapy-by-specific-igg-antibodies-definition-method" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/186797.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">33</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">345</span> Effects of an Educational Program on Nurses Knowledge and Practice Related to Hepatitis-B: Pre-Experimental Design</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20S.%20Mehta">R. S. Mehta</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20N.%20Mandal"> G. N. Mandal </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis-B is the major infectious disease of mankind. In Nepal it is reported that more than 4.3% of Nepalese population at any time in their life has been infected with Hepatitis-B virus (HBV). The objective of this study was to evaluate the effectiveness of planned educational programme regarding knowledge and practice of hepatitis-B among the nurses working at medical units of BPKIHS. Pre-experimental research design was used to conduct the study among the nurses working in medical units of BPKIHS. Total 40 nurses were included in the pre-test and 34 in the post-test. The education intervention was arranged on 24th May 2012 from 2:15 pm to 4:45 pm i.e. two and half hours. After two weeks of education intervention post-test was conducted. Most of the participants (60%) were of the age group of 18-22 years, Hindu (82.5%), and unmarried (65%). After education intervention there is significant differences in knowledge on the components of Hepatitis-B at 0.05 level of significance. There is no difference in the attitude components after post-test except the component patient contaminated with Hepatitis-B must be called as the last patient (p=0.035). It can conclude that hepatitis-B educational program improved knowledge and practice among the nurses. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=educational%20program" title="educational program">educational program</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis-B" title=" Hepatitis-B"> Hepatitis-B</a>, <a href="https://publications.waset.org/abstracts/search?q=pre-experimental%20design" title=" pre-experimental design"> pre-experimental design</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20units" title=" medical units "> medical units </a> </p> <a href="https://publications.waset.org/abstracts/16607/effects-of-an-educational-program-on-nurses-knowledge-and-practice-related-to-hepatitis-b-pre-experimental-design" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16607.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">356</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">344</span> An Assessment of Adverse Events Following Immunization Reporting Pattern of Selected Vaccines in VigiAccess</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Peter%20Yamoah">Peter Yamoah</a>, <a href="https://publications.waset.org/abstracts/search?q=Frasia%20Oosthuizen"> Frasia Oosthuizen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Reporting of Adverse Events Following Immunization continues to be a challenge. Pharmacovigilance centers throughout the world are mandated by the WHO to submit AEFI reports from various countries to a large pool of adverse drug reaction electronic database called Vigibase. Despite the relevant information of AEFI in Vigibase, it is unavailable to the general public. However, the WHO has an alternative website called VigiAccess which is an open access website serving as a repository of reported adverse drug reactions and AEFIs. The aim of the study was to ascertain the reporting pattern of a number of commonly used vaccines in VigiAccess. Methods: VigiAccess was thoroughly searched on the 5th of February 2018 for AEFI reports of measles vaccine, oral polio vaccine (OPV), yellow fever vaccine, pneumococcal vaccine, rotavirus vaccine, meningococcal vaccine, tetanus vaccine and tuberculosis (BCG) vaccine. These were reports from all pharmacovigilance centers in the world from the time they joined the WHO drug monitoring program. Results: After a thorough search in VigiAccess, there were 9,062 measles vaccine AEFIs, 185,829 OPV AEFIs, 24,577 yellow fever vaccine AEFIs, 317,208 pneumococcal vaccine AEFIs, 73,513 rotavirus vaccine AEFIs, 145,447 meningococcal vaccine AEFIs, 22,781 tetanus vaccine AEFIs and 35,556 BCG vaccine AEFIs. Conclusion: The study revealed that out of the eight vaccines studied, pneumococcal vaccines are associated with the highest number of AEFIs whilst measles vaccines were associated with the least AEFIs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=vaccines" title="vaccines">vaccines</a>, <a href="https://publications.waset.org/abstracts/search?q=adverse%20reactions" title=" adverse reactions"> adverse reactions</a>, <a href="https://publications.waset.org/abstracts/search?q=VigiAccess" title=" VigiAccess"> VigiAccess</a>, <a href="https://publications.waset.org/abstracts/search?q=adverse%20event%20reporting" title=" adverse event reporting"> adverse event reporting</a> </p> <a href="https://publications.waset.org/abstracts/97423/an-assessment-of-adverse-events-following-immunization-reporting-pattern-of-selected-vaccines-in-vigiaccess" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97423.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">154</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">343</span> Topic Sentiments toward the COVID-19 Vaccine on Twitter</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Melissa%20Vang">Melissa Vang</a>, <a href="https://publications.waset.org/abstracts/search?q=Raheyma%20Khan"> Raheyma Khan</a>, <a href="https://publications.waset.org/abstracts/search?q=Haihua%20Chen"> Haihua Chen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The coronavirus disease 2019 (COVID‐19) pandemic has changed people's lives from all over the world. More people have turned to Twitter to engage online and discuss the COVID-19 vaccine. This study aims to present a text mining approach to identify people's attitudes towards the COVID-19 vaccine on Twitter. To achieve this purpose, we collected 54,268 COVID-19 vaccine tweets from September 01, 2020, to November 01, 2020, then the BERT model is used for the sentiment and topic analysis. The results show that people had more negative than positive attitudes about the vaccine, and countries with an increasing number of confirmed cases had a higher percentage of negative attitudes. Additionally, the topics discussed in positive and negative tweets are different. The tweet datasets can be helpful to information professionals to inform the public about vaccine-related informational resources. Our findings may have implications for understanding people's cognitions and feelings about the vaccine. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BERT" title="BERT">BERT</a>, <a href="https://publications.waset.org/abstracts/search?q=COVID-19%20vaccine" title=" COVID-19 vaccine"> COVID-19 vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=sentiment%20analysis" title=" sentiment analysis"> sentiment analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=topic%20modeling" title=" topic modeling"> topic modeling</a> </p> <a href="https://publications.waset.org/abstracts/138813/topic-sentiments-toward-the-covid-19-vaccine-on-twitter" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/138813.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">150</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">342</span> Frequency of Hepatitis C Virus in Diagnosed Tuberculosis Cases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Farooq%20Baig">Muhammad Farooq Baig</a>, <a href="https://publications.waset.org/abstracts/search?q=Saleem%20Qadeer"> Saleem Qadeer</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The frequency of hepatitis C virus infection along with tuberculosis has not been widely investigated and very low statistics on rates of hepatitis C virus co-infection in tuberculosis patients. Hepatotoxicity is the major side effect of anti-tuberculosis therapy hepatitis HCVliver disease elevates the chances of hepatotoxicity up-to five folds. Objectives & Aim: To see the frequency of Hepatitis Cvirus infection amongst people with diagnosed Tuberculosis using gene X-pert technique. To evaluate the factors associated with HCVinfection in patients with MTBtuberculosis and to determine sensitivity and specificity of the tests. Study design: Comparative analytical study. Methodology: Three hundred and thirteen patients of tuberculosis diagnosed by Genexpert included while testing hepatitis C virus using immunochromotography rapid test technique, enzyme linked immunosorbent assay method and polymerase chain reaction test for confirmation. Results:Higher frequency of tuberculosis infection in males 57.8%, 42.5% between 20-39 years and 22% of hepatitis C virus infection in tuberculosis patients.The sensitivity of rapid test and enzyme-linked immunosorbent assay was 79% and 96% respectively while the specificity of rapid test and enzyme-linked immunosorbent assay was 91% and 99% respectively. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mycobactrium%20Tuberculosis" title="Mycobactrium Tuberculosis">Mycobactrium Tuberculosis</a>, <a href="https://publications.waset.org/abstracts/search?q=PC%27R" title=" PC'R"> PC'R</a>, <a href="https://publications.waset.org/abstracts/search?q=Gene%20x%20pert" title=" Gene x pert"> Gene x pert</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus" title=" Hepatitis C virus"> Hepatitis C virus</a> </p> <a href="https://publications.waset.org/abstracts/170292/frequency-of-hepatitis-c-virus-in-diagnosed-tuberculosis-cases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170292.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">76</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">341</span> Decreasing Hepatitis B and Tuberculosis Vaccine Coverage Rates among Neonates in Poland, 2015-2017</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aneta%20Nitsch-Osuch">Aneta Nitsch-Osuch</a>, <a href="https://publications.waset.org/abstracts/search?q=Beata%20Pawlus"> Beata Pawlus</a>, <a href="https://publications.waset.org/abstracts/search?q=Maria%20Pawlak"> Maria Pawlak</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Recently, the number of parents who refuse to vaccinate their children or present so-called hesitant behaviors has increased in many developed countries. The study aimed to analyze the completeness and timeliness of vaccinations against hepatitis B and tuberculosis in neonates in a single maternity hospital in Warsaw (Poland). Material and Methods: We analyzed medical records of children born in the hospital between 1st January 2015 and 31st December 2016 and calculated the proportion of newborns not vaccinated on time. Results: The percentage of unvaccinated newborns was similar in the analyzed years: 7.2% in 2015 and 6.7% in 2016. Parental decisions rather than medical contraindications caused non-immunization (4.3% vs. 2.9% in 2015, and 4.7% vs. 2% in 2016). Most parents refused both vaccinations (81%-84%), whereas 7-8% refused only hep B vaccination, and 9-11% refused alone tuberculosis vaccination. The majority of hesitant parents decided to delay both vaccinations (70-80%), while 10-11% of parents chose to delay only one vaccination (hep B). In consecutive years, an increase in the percentage of parents delaying tuberculosis vaccination was reported (10 vs. 19%). Discussion: The increase in the number of newborns who are not correctly vaccinated just after birth due to their parents' decision should be considered non-gradual, both for hepatitis B and tuberculosis. It is necessary to implement effective educational and informative measures targeted at future parents to reinforce positive attitudes towards vaccinations and to dispel doubts about them among parents who are hesitant. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title="hepatitis B">hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=tuberculosis" title=" tuberculosis"> tuberculosis</a>, <a href="https://publications.waset.org/abstracts/search?q=immunization" title=" immunization"> immunization</a>, <a href="https://publications.waset.org/abstracts/search?q=new-borns" title=" new-borns"> new-borns</a>, <a href="https://publications.waset.org/abstracts/search?q=coverage%20rate" title=" coverage rate"> coverage rate</a> </p> <a href="https://publications.waset.org/abstracts/115379/decreasing-hepatitis-b-and-tuberculosis-vaccine-coverage-rates-among-neonates-in-poland-2015-2017" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/115379.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">576</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">340</span> The Regulation of Vaccine-Related Intellectual Property Rights in Light of the Areas of Divergence between the Agreement on Trade-Related Aspects of Intellectual Property Rights and Investment Treaties in the Kingdom of Saudi Arabia and Australia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdulrahman%20Fahim%20M.%20Alsulami">Abdulrahman Fahim M. Alsulami</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The current research seeks to explore the regulation of vaccine-related IP rights in light of the areas of divergence between the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and investment treaties. The study is conducted in the context of the COVID-19 pandemic; therefore, it seems natural that a specific chapter is devoted to the examination of vaccine arrangements related to vaccine supplies. The chapter starts with the examination of a typical vaccine from the perspective of IP rights. It presents the distinctive features of vaccines as pharmaceutical products and investments, reviews the basics of their patent protection, reviews vaccines’ components, and discusses IPR protection of different components of vaccines. The subsection that focuses on vaccine development and licensing reviews vaccine development stages investigates differences between vaccine licensing in different countries and presents barriers to vaccine licensing. The third subsection, at the same time, introduces the existing arrangements related to COVID-19 vaccine supplies, including COVAX arrangements, international organizations’ assistance, and direct negotiations between governments and vaccine manufacturers. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bilateral%20investment%20treaties" title="bilateral investment treaties">bilateral investment treaties</a>, <a href="https://publications.waset.org/abstracts/search?q=COVID-19%20vaccine" title=" COVID-19 vaccine"> COVID-19 vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=IP%20rights" title=" IP rights"> IP rights</a>, <a href="https://publications.waset.org/abstracts/search?q=TRIPs%20agreement" title=" TRIPs agreement"> TRIPs agreement</a> </p> <a href="https://publications.waset.org/abstracts/141167/the-regulation-of-vaccine-related-intellectual-property-rights-in-light-of-the-areas-of-divergence-between-the-agreement-on-trade-related-aspects-of-intellectual-property-rights-and-investment-treaties-in-the-kingdom-of-saudi-arabia-and-australia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/141167.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">183</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">339</span> Effects of Corynebacterium cutis Lysate Administration on Hematology and Biochemistry Parameters with PPR Vaccine</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Burak%20Dik">Burak Dik</a>, <a href="https://publications.waset.org/abstracts/search?q=Oguzhan%20Avci"> Oguzhan Avci</a>, <a href="https://publications.waset.org/abstracts/search?q=Irmak%20Dik"> Irmak Dik</a>, <a href="https://publications.waset.org/abstracts/search?q=Emre%20Bahcivan"> Emre Bahcivan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The objective of this study was to evaluate the effects of alone and combined administration of Peste des petits ruminants (PPR) vaccine with Corynebacterium cutis lysate (CCL) on the hematology and biochemistry parameters levels in sheep. CCL and PPR vaccine changes cell and organ activity. In this study, 12 ewes were divided into equal groups; first group; PPR vaccine was applied only one time 1 mL subcutan of armpit on 6 sheep, and the second group; CCL (1 mL) and PPR vaccine (1 mL) combination were applied only one time subcutan of armpit on 6 sheep. Blood samples were collected before treatment (0. hour, control) and after treatment (1, 3, 7, 14, 21 and 28 days) from the sheep. Plasma and serum samples were evaluated for hematology and biochemistry parameters and there were statistically significant in sheep. In conclusion, combined usage of PPR vaccine with CCL may not influence cells and organs. Repeated CCL treatment with vaccine can create hepatotoxic, renal and bone marrow effects in sheep. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Corynebacterium%20cutis%20lysate" title="Corynebacterium cutis lysate">Corynebacterium cutis lysate</a>, <a href="https://publications.waset.org/abstracts/search?q=hematology" title=" hematology"> hematology</a>, <a href="https://publications.waset.org/abstracts/search?q=peste%20des%20petits%20ruminants" title=" peste des petits ruminants"> peste des petits ruminants</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine" title=" vaccine"> vaccine</a> </p> <a href="https://publications.waset.org/abstracts/50928/effects-of-corynebacterium-cutis-lysate-administration-on-hematology-and-biochemistry-parameters-with-ppr-vaccine" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/50928.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">251</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">338</span> The Impact of Political Polarization on the COVID-19 Vaccine Hesitancy in the United States: A Qualitative Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Peiran%20Ma">Peiran Ma</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This study explored the role of political polarization in an individual's decision of receiving the COVID-19 vaccine. A total of 15 participants participated in individual interviews and focus group discussions about the relationships among domestic political polarization, vaccine hesitancy, and behavioral responses to the COVID-19 pandemic. Political affiliation affected an individual’s decision on the COVID-19 vaccination, such that people who identified as Liberals and Democrats were more accepting of the vaccine. On the other hand, the level of influence declined over time (2020-2022) when the general conception of COVID-19 immunization shifted from political to personal. Results provided qualitative support to the previously identified positive relationship between divided political opinions and COVID-19 vaccine hesitancy and highlighted the decreasing trend in the power of political polarization in vaccination and the existence of other factors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=COVID-19" title="COVID-19">COVID-19</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine%20hesitancy" title=" vaccine hesitancy"> vaccine hesitancy</a>, <a href="https://publications.waset.org/abstracts/search?q=political%20polarization" title=" political polarization"> political polarization</a>, <a href="https://publications.waset.org/abstracts/search?q=partisanship" title=" partisanship"> partisanship</a>, <a href="https://publications.waset.org/abstracts/search?q=ideology" title=" ideology"> ideology</a> </p> <a href="https://publications.waset.org/abstracts/165405/the-impact-of-political-polarization-on-the-covid-19-vaccine-hesitancy-in-the-united-states-a-qualitative-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/165405.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">84</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">337</span> Vaccine Development for Newcastle Disease Virus in Poultry</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Asif%20Rasheed">Muhammad Asif Rasheed</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Newcastle disease virus (NDV), an avian orthoavulavirus, is a causative agent of Newcastle disease named (NDV) and can cause even the epidemics when the disease is not treated. Previously several vaccines based on attenuated and inactivated viruses have been reported, which are rendered useless with the passage of time due to versatile changes in viral genome. Therefore, we aimed to develop an effective multi-epitope vaccine against the haemagglutinin neuraminidase (HN) protein of 26 NDV strains from Pakistan through a modern immunoinformatic approaches. As a result, a vaccine chimaera was constructed by combining T-cell and B-cell epitopes with the appropriate linkers and adjuvant. The designed vaccine was highly immunogenic, non-allergen, and antigenic; therefore, the potential 3D-structureof multi epitope vaccine was constructed, refined, and validated. A molecular docking study of a multiepitope vaccine candidate with the chicken Toll-like receptor-4 indicated successful binding. An In silico immunological simulation was used to evaluate the candidate vaccine's ability to elicit an effective immune response. According to the computational studies, the proposed multiepitope vaccine is physically stable and may induce immune responses, whichsuggested it a strong candidate against 26 Newcastle disease virus strains from Pakistan. A wet lab study is under process to confirm the results. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=epitopes" title="epitopes">epitopes</a>, <a href="https://publications.waset.org/abstracts/search?q=newcastle%20disease%20virus" title=" newcastle disease virus"> newcastle disease virus</a>, <a href="https://publications.waset.org/abstracts/search?q=paramyxovirus%20virus" title=" paramyxovirus virus"> paramyxovirus virus</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine" title=" vaccine"> vaccine</a> </p> <a href="https://publications.waset.org/abstracts/150531/vaccine-development-for-newcastle-disease-virus-in-poultry" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/150531.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">120</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">336</span> Dynamic Modelling of Hepatitis B Patient Using Sihar Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alakija%20Temitope%20Olufunmilayo">Alakija Temitope Olufunmilayo</a>, <a href="https://publications.waset.org/abstracts/search?q=Akinyemi"> Akinyemi</a>, <a href="https://publications.waset.org/abstracts/search?q=Yagba%20Joy"> Yagba Joy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis is the inflammation of the liver tissue that can cause whiteness of the eyes (Jaundice), lack of appetite, vomiting, tiredness, abdominal pain, diarrhea. Hepatitis is acute if it resolves within 6 months and chronic if it last longer than 6 months. Acute hepatitis can resolve on its own, lead to chronic hepatitis or rarely result in acute liver failure. Chronic hepatitis may lead to scarring of the liver (Cirrhosis), liver failure and liver cancer. Modelling Hepatitis B may become necessary in order to reduce its spread. So, dynamic SIR model can be used. This model consists of a system of three coupled non-linear ordinary differential equation which does not have an explicit formula solution. It is an epidemiological model used to predict the dynamics of infectious disease by categorizing the population into three possible compartments. In this study, a five-compartment dynamic model of Hepatitis B disease was proposed and developed by adding control measure of sensitizing the public called awareness. All the mathematical and statistical formulation of the model, especially the general equilibrium of the model, was derived, including the nonlinear least square estimators. The initial parameters of the model were derived using nonlinear least square embedded in R code. The result study shows that the proportion of Hepatitis B patient in the study population is 1.4 per 1,000,000 populations. The estimated Hepatitis B induced death rate is 0.0108, meaning that 1.08% of the infected individuals die of the disease. The reproduction number of Hepatitis B diseases in Nigeria is 6.0, meaning that one individual can infect more than 6.0 people. The effect of sensitizing the public on the basic reproduction number is significant as the reproduction number is reduced. The study therefore recommends that programme should be designed by government and non-governmental organization to sensitize the entire Nigeria population in order to reduce cases of Hepatitis B disease among the citizens. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title="hepatitis B">hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=modelling" title=" modelling"> modelling</a>, <a href="https://publications.waset.org/abstracts/search?q=non-linear%20ordinary%20differential%20equation" title=" non-linear ordinary differential equation"> non-linear ordinary differential equation</a>, <a href="https://publications.waset.org/abstracts/search?q=sihar%20model" title=" sihar model"> sihar model</a>, <a href="https://publications.waset.org/abstracts/search?q=sensitization" title=" sensitization"> sensitization</a> </p> <a href="https://publications.waset.org/abstracts/171002/dynamic-modelling-of-hepatitis-b-patient-using-sihar-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/171002.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">335</span> The Impact of Pediatric Cares, Infections and Vaccines on Community and People’s Lives</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nashed%20Atef%20Nashed%20Farag">Nashed Atef Nashed Farag</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Reporting adverse events following vaccination remains a challenge. WHO has mandated pharmacovigilance centers around the world to submit Adverse Events Following Immunization (AEFI) reports from different countries to a large electronic database of adverse drug event data called Vigibase. Despite sufficient information about AEFIs on Vigibase, they are not available to the general public. However, the WHO has an alternative website called VigiAccess, an open-access website that serves as an archive for reported adverse reactions and AEFIs. The aim of the study was to establish a reporting model for a number of commonly used vaccines in the VigiAccess system. Methods: On February 5, 2018, VigiAccess comprehensively searched for ESSI reports on the measles vaccine, oral polio vaccine (OPV), yellow fever vaccine, pneumococcal vaccine, rotavirus vaccine, meningococcal vaccine, tetanus vaccine, and tuberculosis vaccine (BCG). These are reports from all pharmacovigilance centers around the world since they joined the WHO Drug Monitoring Program. Results: After an extensive search, VigiAccess found 9,062 AEFIs from the measles vaccine, 185,829 AEFIs from the OPV vaccine, 24,577 AEFIs from the yellow fever vaccine, 317,208 AEFIs from the pneumococcal vaccine, 73,513 AEFIs from the rotavirus vaccine, and 145,447 AEFIs from meningococcal cal vaccine, 22,781 EI FI vaccines against tetanus and 35,556 BCG vaccines against AEFI. Conclusion: The study found that among the eight vaccines examined, pneumococcal vaccines were associated with the highest number of AEFIs, while measles vaccines were associated with the fewest AEFIs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=surgical%20approach" title="surgical approach">surgical approach</a>, <a href="https://publications.waset.org/abstracts/search?q=anatomical%20approach" title=" anatomical approach"> anatomical approach</a>, <a href="https://publications.waset.org/abstracts/search?q=decompression" title=" decompression"> decompression</a>, <a href="https://publications.waset.org/abstracts/search?q=axillary%20nerve" title=" axillary nerve"> axillary nerve</a>, <a href="https://publications.waset.org/abstracts/search?q=quadrangular%20space%20adverse%20events%20following%20immunization" title=" quadrangular space adverse events following immunization"> quadrangular space adverse events following immunization</a>, <a href="https://publications.waset.org/abstracts/search?q=cameroon" title=" cameroon"> cameroon</a>, <a href="https://publications.waset.org/abstracts/search?q=COVID-19%20vaccines" title=" COVID-19 vaccines"> COVID-19 vaccines</a>, <a href="https://publications.waset.org/abstracts/search?q=nOPV" title=" nOPV"> nOPV</a>, <a href="https://publications.waset.org/abstracts/search?q=ODK%20vaccines" title=" ODK vaccines"> ODK vaccines</a>, <a href="https://publications.waset.org/abstracts/search?q=adverse%20reactions" title=" adverse reactions"> adverse reactions</a>, <a href="https://publications.waset.org/abstracts/search?q=VigiAccess" title=" VigiAccess"> VigiAccess</a>, <a href="https://publications.waset.org/abstracts/search?q=adverse%20event%20reporting" title=" adverse event reporting"> adverse event reporting</a> </p> <a href="https://publications.waset.org/abstracts/184332/the-impact-of-pediatric-cares-infections-and-vaccines-on-community-and-peoples-lives" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/184332.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">72</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">334</span> A Medical Resource Forecasting Model for Emergency Room Patients with Acute Hepatitis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20J.%20Kuo">R. J. Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Cheng"> W. C. Cheng</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Lien"> W. C. Lien</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20J.%20Yang"> T. J. Yang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Taiwan is a hyper endemic area for the Hepatitis B virus (HBV). The estimated total number of HBsAg carriers in the general population who are more than 20 years old is more than 3 million. Therefore, a case record review is conducted from January 2003 to June 2007 for all patients with a diagnosis of acute hepatitis who were admitted to the Emergency Department (ED) of a well-known teaching hospital. The cost for the use of medical resources is defined as the total medical fee. In this study, principal component analysis (PCA) is firstly employed to reduce the number of dimensions. Support vector regression (SVR) and artificial neural network (ANN) are then used to develop the forecasting model. A total of 117 patients meet the inclusion criteria. 61% patients involved in this study are hepatitis B related. The computational result shows that the proposed PCA-SVR model has superior performance than other compared algorithms. In conclusion, the Child-Pugh score and echogram can both be used to predict the cost of medical resources for patients with acute hepatitis in the ED. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20hepatitis" title="acute hepatitis">acute hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20resource%20cost" title=" medical resource cost"> medical resource cost</a>, <a href="https://publications.waset.org/abstracts/search?q=artificial%20neural%20network" title=" artificial neural network"> artificial neural network</a>, <a href="https://publications.waset.org/abstracts/search?q=support%20vector%20regression" title=" support vector regression"> support vector regression</a> </p> <a href="https://publications.waset.org/abstracts/23255/a-medical-resource-forecasting-model-for-emergency-room-patients-with-acute-hepatitis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23255.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">422</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">333</span> An Investigation of Etiology of Liver Cirrhosis and Its Complications with Other Co-morbid Diseases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tayba%20Akram">Tayba Akram</a> </p> <p class="card-text"><strong>Abstract:</strong></p> our main objective of this study is to work on the etiology of liver cirrhosis, to find basic reasons and causes of liver damage, and to find the pattern of liver cirrhosis in hepatic patients either suffering from hepatitis B/C or simple jaundice. We can evaluate medical treatment and the latest trends in patients suffering from liver cirrhosis. We can evaluate the side effects and adverse effects induced by drug therapy used to treat liver cirrhosis. The conclusion is based on the etiology of liver cirrhosis. The most common cause of liver cirrhosis is the viral Hepatitis C virus. Other common causes of liver cirrhosis that are estimated from our research are Hepatitis B virus, Diabetes Mellitus, Ascites, and very rarely found Hepatitis D virus. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=etiology" title="etiology">etiology</a>, <a href="https://publications.waset.org/abstracts/search?q=liver" title=" liver"> liver</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title=" cirrhosis"> cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=co-morbid%20diseases" title=" co-morbid diseases"> co-morbid diseases</a> </p> <a href="https://publications.waset.org/abstracts/193100/an-investigation-of-etiology-of-liver-cirrhosis-and-its-complications-with-other-co-morbid-diseases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193100.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">12</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">332</span> Hepatitis B Prevalence in Institutionalized Intellectually Disabled Children</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Maryam%20Vaezjalali">Maryam Vaezjalali</a>, <a href="https://publications.waset.org/abstracts/search?q=Foad%20Davoodbeglou"> Foad Davoodbeglou</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehrnaz%20Mesdaghi"> Mehrnaz Mesdaghi</a>, <a href="https://publications.waset.org/abstracts/search?q=Hossein%20Goudarzi"> Hossein Goudarzi</a>, <a href="https://publications.waset.org/abstracts/search?q=Fariba%20Shojaei"> Fariba Shojaei</a>, <a href="https://publications.waset.org/abstracts/search?q=Hourieh%20Aram"> Hourieh Aram </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatitis B virus (HBV) infection causes chronic infection in human population, with high mortality. Some people are more susceptible to this infection. One of the high risk communities is mentally retarded children, who are institutionalized. Special conditions in these centers predispose children for HBV infection and transmission to healthy people. In this study our objective was to determine the prevalence of HBV infection among institutionalized mentally retarded children and study its associated risk factors. Materials and methods: In this study, 250 mentally retarded children (younger than 14 years old) were included. They were living in 5 nursing institutions, located in different parts of Tehran. HBsAg was measured in the sera of these patients by ELISA method. Results: Among 250 children, 20 children (8%) were HBsAg positive. HBV infection in girls was more than boys (11% to 5.6%). Among the types of mental retardation, children with cerebral palsy had the highest positive result for HBsAg. The most HBV infection (28.5%) was seen in children with longest duration of being institutionalized (10 to 11 years). Vaccinated children were more HBsAg positive (8.7%) than non-vaccinated children (5.3%). However, no significant relationship was observed between any of these factors and HBsAg positivity. Conclusion: Despite improvement of people’s health condition and implementation of HBV vaccination, the prevalence of HBV infection is high in institutionalized mentally retarded children, which highlights the need for active measures to reduce this infection among this high risk population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title="hepatitis B virus">hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=HBV%20vaccine" title=" HBV vaccine"> HBV vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=intellectually%20disabled%20children" title=" intellectually disabled children"> intellectually disabled children</a>, <a href="https://publications.waset.org/abstracts/search?q=mentally%20retarded" title=" mentally retarded"> mentally retarded</a> </p> <a href="https://publications.waset.org/abstracts/36248/hepatitis-b-prevalence-in-institutionalized-intellectually-disabled-children" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/36248.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">481</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">331</span> An In-silico Pharmacophore-Based Anti-Viral Drug Development for Hepatitis C Virus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Romasa%20Qasim">Romasa Qasim</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20M.%20Sayedur%20Rahman"> G. M. Sayedur Rahman</a>, <a href="https://publications.waset.org/abstracts/search?q=Nahid%20Hasan"> Nahid Hasan</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Shazzad%20Hosain"> M. Shazzad Hosain</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Millions of people worldwide suffer from Hepatitis C, one of the fatal diseases. Interferon (IFN) and ribavirin are the available treatments for patients with Hepatitis C, but these treatments have their own side-effects. Our research focused on the development of an orally taken small molecule drug targeting the proteins in Hepatitis C Virus (HCV), which has lesser side effects. Our current study aims to the Pharmacophore based drug development of a specific small molecule anti-viral drug for Hepatitis C Virus (HCV). Drug designing using lab experimentation is not only costly but also it takes a lot of time to conduct such experimentation. Instead in this in silico study, we have used computer-aided techniques to propose a Pharmacophore-based anti-viral drug specific for the protein domains of the polyprotein present in the Hepatitis C Virus. This study has used homology modeling and ab initio modeling for protein 3D structure generation followed by pocket identification in the proteins. Drug-able ligands for the pockets were designed using de novo drug design method. For ligand design, pocket geometry is taken into account. Out of several generated ligands, a new Pharmacophore is proposed, specific for each of the protein domains of HCV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=pharmacophore-based%20drug%20design" title="pharmacophore-based drug design">pharmacophore-based drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=anti-viral%20drug" title=" anti-viral drug"> anti-viral drug</a>, <a href="https://publications.waset.org/abstracts/search?q=in-silico%20drug%20design" title=" in-silico drug design"> in-silico drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus%20%28HCV%29" title=" Hepatitis C virus (HCV)"> Hepatitis C virus (HCV)</a> </p> <a href="https://publications.waset.org/abstracts/64266/an-in-silico-pharmacophore-based-anti-viral-drug-development-for-hepatitis-c-virus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/64266.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">271</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">330</span> COVID-19 Vaccine Hesitancy: The Role of Existential Concerns in Individual’s Decisions Regarding the Vaccine Uptake</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vittoria%20Franchina">Vittoria Franchina</a>, <a href="https://publications.waset.org/abstracts/search?q=Laura%20Salerno"> Laura Salerno</a>, <a href="https://publications.waset.org/abstracts/search?q=Rubinia%20Celeste%20Bonfanti"> Rubinia Celeste Bonfanti</a>, <a href="https://publications.waset.org/abstracts/search?q=Gianluca%20Lo%20Coco"> Gianluca Lo Coco</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This study examines the relationships between existential concerns (ECs), basic psychological needs (BPNs), vaccine hesitancy (VH), and the mediating role of negative attitudes toward COVID-19 vaccines. A cross-sectional survey was carried out on a sample of two-hundred eighty-seven adults (Mage = 36.04 (12.07); 59.9% females). Participants were recruited online through clickworker and filled in measures on existential concerns, basic psychological needs, attitudes toward COVID-19 vaccines, and vaccine hesitancy for Pfizer-BioNTech and Astrazeneca vaccines separately. Structural equation modelling showed that existential concerns were related to Pfizer-BioNTech and Astrazeneca vaccine hesitancy both directly and indirectly through negative attitudes toward possible side effects of COVID-19 vaccines. The present study has identified several predictive factors relating to the intention to uptake vaccination to protect against COVID-19 in Italy. Specifically, these findings suggest a causal link between existential concerns, attitudes, and vaccine hesitancy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=COVID-19" title="COVID-19">COVID-19</a>, <a href="https://publications.waset.org/abstracts/search?q=existential%20concerns" title=" existential concerns"> existential concerns</a>, <a href="https://publications.waset.org/abstracts/search?q=Pfizer-BioNTech%20and%20Astrazeneca%20vaccines" title=" Pfizer-BioNTech and Astrazeneca vaccines"> Pfizer-BioNTech and Astrazeneca vaccines</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine%20hesitancy" title=" vaccine hesitancy"> vaccine hesitancy</a> </p> <a href="https://publications.waset.org/abstracts/149591/covid-19-vaccine-hesitancy-the-role-of-existential-concerns-in-individuals-decisions-regarding-the-vaccine-uptake" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/149591.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">99</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">329</span> Prevalence Determination of Hepatitis D Virus Genotypes among HBsAg Positive Patients in Kerman Province of Iran</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Khabat%20Barkhordari">Khabat Barkhordari</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Mohammad%20Arabzadeh"> Ali Mohammad Arabzadeh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis delta virus (HDV) is a RNA virus that needs the function of hepatitis B virus (HBV) for its propagation and assembly. Infection by HDV can occur spontaneously with HBV infection and cause acute hepatitis or develop as secondary infection in HBV suffering patients. Based on genome sequence analysis, HDV has several genotypes which show broad geographic and diverse clinical features. The aim of current study is determine the prevalence of hepatitis delta virus genotype in patients with positive HBsAg in Kerman province of Iran. This cross-sectional study a total of 400 patients with HBV infection attending the clinic center of Besat from 2012 to 2014 were included. We carried out ELISA to detect anti-HDV antibodies. Those testing positive were analyzed further for HDV-RNA and for genotyping using restriction fragment length polymorphism (RFLP) and RT-nested PCR- sequencing. Among 400 patients in this study, 67 cases (16.75 %) were containing anti-HDV antibody which we found HDV RNA in just 7 (1.75%) serum samples. Analysis of these 7 positive HDV showed that all of them have genotype I. According to current study the HDV prevalence in Kerman is higher than the reported prevalence of 6.6% for Iran as a whole and clade 1 (genotype 1) is the predominant clade of HDV in Kerman. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=genotyping" title="genotyping">genotyping</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20delta%20virus" title=" hepatitis delta virus"> hepatitis delta virus</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20epidemiology" title=" molecular epidemiology"> molecular epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=Kerman" title=" Kerman"> Kerman</a>, <a href="https://publications.waset.org/abstracts/search?q=Iran" title=" Iran"> Iran</a> </p> <a href="https://publications.waset.org/abstracts/36576/prevalence-determination-of-hepatitis-d-virus-genotypes-among-hbsag-positive-patients-in-kerman-province-of-iran" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/36576.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">294</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">328</span> Neutralizing Antibody Response against Inactivated FMDV Type O/IRN/2010 Vaccine by Electron Beam in BALB/C Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=F.%20Motamedi%20Sedeh">F. Motamedi Sedeh</a>, <a href="https://publications.waset.org/abstracts/search?q=Sh.%20Chahardoli"> Sh. Chahardoli</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Mahravani"> H. Mahravani</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Harzandi"> N. Harzandi</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Sotoodeh"> M. Sotoodeh</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20K.%20Shafaei"> S. K. Shafaei </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Foot-and-mouth disease virus (FMDV) is the most economically important disease of livestock. The aim of the study is inactivation of FMD virus type O/IRN/2010 by electron beam without antigenic changes as electron radio vaccine. The BALB/C mice were divided into three groups, each group containing five mice. Three groups of mice were inoculated with conventional vaccine and electron beam irradiated vaccine FMDV type O/IRN/2010 subcutaneously three weeks interval, the final group as negative control. The sera were separated from the blood samples of mice 14 days after last vaccination and tested for the presence of antibodies against FMDV type O/IRN/2010 by serum neutralization test. The Serum Neutralization Test (SNT) was carried out and antibody titration was calculated according to the Kraber protocol. The results of the SNT in three groups of mice showed the titration of neutralizing antibody in the vaccinated mice groups; electron radio vaccine and conventional vaccine were significantly higher than negative control group (P<0.05). Therefore, the radio vaccine is a good candidate to immunize animals against FMDV type O/IRN/2010. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=FMDV%20type%20O%2FIRN%2F2010" title="FMDV type O/IRN/2010">FMDV type O/IRN/2010</a>, <a href="https://publications.waset.org/abstracts/search?q=neutralizing%20antibody%20response" title=" neutralizing antibody response"> neutralizing antibody response</a>, <a href="https://publications.waset.org/abstracts/search?q=electron%20beam" title=" electron beam"> electron beam</a>, <a href="https://publications.waset.org/abstracts/search?q=radio%20vaccine" title=" radio vaccine"> radio vaccine</a> </p> <a href="https://publications.waset.org/abstracts/11949/neutralizing-antibody-response-against-inactivated-fmdv-type-oirn2010-vaccine-by-electron-beam-in-balbc-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/11949.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">317</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">327</span> The Impact of Social Media Exposure on COVID- 19 Vaccine Hesitancy “A Comparative Study on the Public in Egypt and the United Arab Emirates”</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Lamiaa%20Shehata">Lamiaa Shehata</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The current (COVID-19) pandemic is one of the international crises, and a lot of efforts have been directed toward the improvement of efficient vaccines, however vaccine hesitancy is one of the universal menaces that make the fulfillment of society immunity very hard. The World Health Organization acknowledges vaccine hesitancy as the society’s maximum risk to people's health protection, especially in little and moderate-revenue nations. Social media is strong in observing audience behaviors and evaluating the circulation, which would supply useful data for strategy makers. It has a significant function in spreading facts during the pandemic, it could assist to boost protective manners. The objective of this study is to determine the effects of social media exposure on vaccine hesitancy. Data were collected using a survey in a form of a structured questionnaire conducted during December 2021- January 2022 using convenient sampling techniques (680) in Egypt and the United Arab Emirates. The results revealed that there was a significant relationship between the high exposure to social media and the refusal of the Covid19 vaccine also, the percentage of the refusal of the vaccine is higher in Egypt, however, UAE forced people to take the vaccine. Furthermore, public attitudes toward COVID-19 vaccination vary from gender and region. In conclusion, policymakers must adjust their policies through the use of social media to immediate actions to vaccine-related news to support vaccination approval. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=COVID-19" title="COVID-19">COVID-19</a>, <a href="https://publications.waset.org/abstracts/search?q=hesitancy" title=" hesitancy"> hesitancy</a>, <a href="https://publications.waset.org/abstracts/search?q=social%20media" title=" social media"> social media</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccine" title=" vaccine"> vaccine</a> </p> <a href="https://publications.waset.org/abstracts/147964/the-impact-of-social-media-exposure-on-covid-19-vaccine-hesitancy-a-comparative-study-on-the-public-in-egypt-and-the-united-arab-emirates" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/147964.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">139</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=10">10</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=11">11</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=12">12</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>